论文部分内容阅读
目的:探讨用新城鸡瘟病毒修饰的自体肿瘤细胞疫苗(ATV-NDV)对食管、贲门癌患者临床应用的意义。方法:采用SP一步法和双抗体夹心酶联免疫吸附试验法(ELISA法),对52例接种瘤苗食管、贲门癌手术患者和68例未接种瘤苗食管、贲门癌手术前后的外周血NK活性、T淋巴细胞亚群、白细胞介素-2(IL-2)、白细胞介素-2受体(IL-2R)、白细胞介素-6(IL-6)和肿瘤坏死因子(TNF)进行检测,用40例正常人作对照组。结果:食管、贲门癌手术患者瘤苗接种治疗后细胞免疫指标CD3、CD4百分率和CD4/CD8比值明显增加,CD8百分率明显下降,NK活性无明显变化;食管、贲门癌患者IL-2R、IL-6、TNF水平明显高于正常对照组(P<0.01),而IL-2水平明显较低(P<0.01)。患者术后IL-2R、IL-6较术前明显增高(P<0.01),IL-2、TNF较术前有所降低(P>0.05)。经过免疫接种后,患者IL-2较接种前明显增高(P<0.01),而IL-2R、IL-6、TNF较接种前明显降低(P<0.01)。结论:新城鸡瘟病毒修饰的自体肿瘤细胞疫苗(ATV-NDV)是一种特异性较高的安全有效的免疫制剂,其远期疗效仍在进一步观察中。
Objective: To investigate the clinical application of auto-tumor cell vaccine (ATV-NDV) modified with poultry plague virus in the treatment of esophageal and gastric cardia cancer patients. Methods: Using SP one-step method and double-antibody sandwich enzyme-linked immunosorbent assay (ELISA method), 52 cases of tumor inoculation esophageal and cardiac surgery and 68 cases of non-tumor vaccine esophageal and cardiac cancer before and after surgery in peripheral blood NK Activity, T lymphocyte subsets, interleukin-2 (IL-2), interleukin-2 receptor (IL-2R), interleukin- 6 (IL-6) and tumor necrosis factor (TNF) Test, with 40 normal controls. Results: The percentage of CD3, CD4 and CD4 / CD8 increased significantly after tumor inoculation in esophageal and gastric cardia cancer patients, the percentage of CD8 decreased and the activity of NK had no significant difference. The expressions of IL-2R and IL- 6, TNF levels were significantly higher than the normal control group (P <0.01), while IL-2 levels were significantly lower (P <0.01). The postoperative IL-2R and IL-6 levels in patients were significantly higher than those before operation (P <0.01). IL-2 and TNF levels were lower than those before operation (P> 0.05). After immunization, the level of IL-2 in patients was significantly higher than that before inoculation (P <0.01), while the levels of IL-2R, IL-6 and TNF were significantly lower than those before inoculation (P <0.01). Conclusion: Newcastle disease virus self-modified tumor cell vaccine (ATV-NDV) is a highly specific and safe immune vaccine, its long-term efficacy is still under further observation.